Schering-Plough Will Eye Primary Care Acquisitions To Complement Vytorin, Zetia

CEO Hassan vows not to repeat mistakes of Schering's past by relying on the cholesterol agents to carry the business for the long-term. Bayer's oral Factor Xa inhibitor is a potential acquisition candidate, depending on how the antithrombotic fares in Phase III.